Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 2/20 | 0.35 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.35 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.35 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.35 |
| ▸ | HTR3B | O95264 | 1/20 | 0.35 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.35 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.35 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.35 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.35 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.35 |
| ▸ | HRH1 | P35367 | 1/20 | 0.35 |
| ▸ | DRD3 | P35462 | 1/20 | 0.35 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.35 |
| ▸ | HTR3A | P46098 | 1/20 | 0.35 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4510414 | 0.84 | OPRM1 (0.35) | OPRL1OPRM1OPRD1OPRK1ADRA2A | |
| SCHEMBL4494937 | 0.84 | HCRTR1 (0.35) | OPRL1OPRM1OPRD1OPRK1ADRA2A | |
| SCHEMBL261440 | 0.78 | MAPT (0.45) | — | |
| SCHEMBL16353671 | 0.77 | HTR2C (0.47) | — | |
| SCHEMBL6854090 | 0.77 | PARP1 (0.56) | HTR3BADRA2AKCNE1ADRA2CCHRM3 | |
| SCHEMBL19698078 | 0.77 | HTR3B (0.40) | HTR3BADRA2AKCNE1ADRA2CCHRM3 | |
| SCHEMBL31037184 | 0.77 | PARP1 (0.56) | HTR3BADRA2AKCNE1ADRA2CCHRM3 | |
| SCHEMBL21556355 | 0.77 | HTR3B (0.40) | HTR3BADRA2AKCNE1ADRA2CCHRM3 | |
| SCHEMBL829452 | 0.76 | TSHR (0.43) | HTR3BADRA2AKCNE1ADRA2CCHRM3 | |
| SCHEMBL743887 | 0.76 | HTR2A (0.37) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 96 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4211653-A | — | — | None | — | — | JP | disclosed |
| JP-4230664-A | — | — | None | — | — | JP | disclosed |
| US-8252814-B2 | Agents and crystals for improving excretory potency of urinary bladder | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-08-28 | — | — | US | disclosed |
| US-20090264467-A1 | Agents and crystals for improving excretory potency of urinary bladder | ISHIHARA YUJI | 2009-10-22 | — | — | US | disclosed |
| US-7462628-B2 | Preventives/remedies for urinary disturbance | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-12-09 | — | — | US | disclosed |
| EP-1891954-A2 | Acetylcholinesterase inhibitors for improving excretory potency of urinary bladder | Takeda Pharmaceutical Company Limited (JP) | 2008-02-27 | — | — | EP | disclosed |
| US-20070232538-A1 | Uses of polypeptides | TAKEDA PHARMACEUTICAL COMPANY, LTD (JP) | 2007-10-04 | — | — | US | disclosed |
| US-20070027138-A1 | Derivatives and analogs of galanthamine | SANOCHEMIA PHARMAZEUTIKA AKTIENGESELLSCHAFT | 2007-02-01 | — | — | US | disclosed |
| US-20070021391-A1 | Preventive/remedy for urinary disturbance | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-01-25 | — | — | US | disclosed |
| US-7166588-B2 | Derivatives and analogs of galanthamine | SANOCHEMIA PHARMAZEUTIKA AKTIENGESELLSCHAFT (AT) | 2007-01-23 | — | — | US | disclosed |
| EP-0444851-A2 | Hexahydrobenz[CD]indoles and processes for preparation thereof | ELI LILLY AND COMPANY (US) | 1991-09-04 | — | — | EP | disclosed |
| EP-0444854-A2 | 6-Substituted hexahydrobenz[cd]indoles | ELI LILLY AND COMPANY (US) | 1991-09-04 | — | — | EP | disclosed |
| EP-0444851-A2 | Hexahydrobenz[CD]indoles and processes for preparation thereof | ELI LILLY AND COMPANY (US) | 1991-09-04 | — | — | EP | disclosed |
| EP-0444854-A2 | 6-Substituted hexahydrobenz[cd]indoles | ELI LILLY AND COMPANY (US) | 1991-09-04 | — | — | EP | disclosed |
| EP-0444853-A2 | Hexahydrobenz[cd]indoles | ELI LILLY AND COMPANY (US) | 1991-09-04 | — | — | EP | disclosed |
| US-5039820-A | Nervous system disorders | ELI LILLY AND COMPANY (US) | 1991-08-13 | — | — | US | disclosed |
| US-5026869-A | Antidepressants; serotonin antagonists | ELI LILLY AND COMPANY (US) | 1991-06-25 | — | — | US | disclosed |
| US-4983622-A | Antidepressants | ELI LILLY AND COMPANY (US) | 1991-01-08 | — | — | US | disclosed |
| EP-0153083-B1 | 6-SUBSTITUTED-4-DIALKYLAMINOTETRAHYDROBENZ(C,D)INDOLES | ELI LILLY AND COMPANY (US) | 1990-05-23 | — | — | EP | disclosed |
| US-4576959-A | ANTIDEPRESSANTS | ELI LILLY AND COMPANY (US) | 1986-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021391-A1 | Preventive/remedy for urinary disturbance | ACHE, BCHE, CHAT | OPRL1 1079/4885OPRM1 1053/4885OPRD1 1349/4885 |
| US-20070027138-A1 | Derivatives and analogs of galanthamine | GALR2, GALR1, GALR3 | OPRL1 203/4885OPRM1 69/4885OPRD1 138/4885 |
| US-20090264467-A1 | Agents and crystals for improving excretory potency of urinary bladder | ACHE, BCHE, PDE7A | OPRL1 1806/4885OPRM1 974/4885OPRD1 1662/4885 |
| US-20070232538-A1 | Uses of polypeptides | NPSR1, SCTR, GRPR | OPRL1 23/4885OPRM1 377/4885OPRD1 184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.